Literature DB >> 28450207

Drug release studies from lipid nanoparticles in physiological media by a new DSC method.

Elin Roese1, Heike Bunjes2.   

Abstract

Lipid nanoparticles are an interesting parenteral delivery system for poorly water-soluble drugs. In order to approach physiological conditions when conducting release studies from such systems the release media should preferentially contain lipophilic acceptor compartments such as lipoproteins or other colloidal lipophilic components. In practice, drug release studies under such close to physiological conditions may be complicated by the small size of lipid nanoparticles, which is in the same range as that of the potential acceptor particles. This study describes a novel differential scanning calorimetry (DSC) method for drug release measurements which works without separation of donor and acceptor particles. The technique is based on measuring the crystallization temperature of trimyristin nanoparticles by DSC. The crystallization temperature of the nanoparticles decreases proportionally with the amount of active ingredient incorporated and thus increases as a result of drug release. Liquid trimyristin nanoparticles loaded with fenofibrate, orlistat, tocopherol acetate and ubidecarenone were studied in three different release media with increasing complexity and comparability to physiological conditions: a rapeseed oil nanoemulsion, porcine serum and porcine blood. Using the new method, a correlation between release behavior and drug lipophilicity was observed: the higher the logP value of the drug, the slower the release. The extent of drug release was influenced by partition equilibrium as indicated by increased drug release in the rapeseed oil nanoemulsion compared to porcine serum and blood.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Crystallization; Differential scanning calorimetry; Drug release; Lipid nanoparticles; Physiological conditions; logP

Mesh:

Substances:

Year:  2017        PMID: 28450207     DOI: 10.1016/j.jconrel.2017.04.032

Source DB:  PubMed          Journal:  J Control Release        ISSN: 0168-3659            Impact factor:   9.776


  6 in total

1.  Combination Therapy of Metastatic Castration-Recurrent Prostate Cancer: Hyaluronic Acid Decorated, Cabazitaxel-Prodrug and Orlistat Co-Loaded Nano-System.

Authors:  Zhen Qu; Yuning Ren; Hongyu Shen; Huihui Wang; Lijie Shi; Deyong Tong
Journal:  Drug Des Devel Ther       Date:  2021-08-20       Impact factor: 4.162

2.  Taribavirin and 5-Fluorouracil-Loaded Pegylated-Lipid Nanoparticle Synthesis, p38 Docking, and Antiproliferative Effects on MCF-7 Breast Cancer.

Authors:  Ahmed A Abd-Rabou; Dhruba J Bharali; Shaker A Mousa
Journal:  Pharm Res       Date:  2018-02-27       Impact factor: 4.200

3.  Transfer of Lipophilic Drugs from Nanoemulsions into Lipid-Containing Alginate Microspheres.

Authors:  Sabrina Knoke; Heike Bunjes
Journal:  Pharmaceutics       Date:  2021-01-28       Impact factor: 6.321

4.  New Nanoparticle Formulation for Cyclosporin A: In Vitro Assessment.

Authors:  Amandine Gendron; Natalie Lan Linh Tran; Julie Laloy; Romain Brusini; Aurélie Rachet; Frédéric Gobeaux; Valérie Nicolas; Pierre Chaminade; Sonia Abreu; Didier Desmaële; Mariana Varna
Journal:  Pharmaceutics       Date:  2021-01-12       Impact factor: 6.321

5.  Protein corona formation moderates the release kinetics of ion channel antagonists from transferrin-functionalized polymeric nanoparticles.

Authors:  Priya S R Naidu; Eleanor Denham; Carole A Bartlett; Terry McGonigle; Nicolas L Taylor; Marck Norret; Nicole M Smith; Sarah A Dunlop; K Swaminathan Iyer; Melinda Fitzgerald
Journal:  RSC Adv       Date:  2020-01-15       Impact factor: 4.036

6.  Combined and targeted drugs delivery system for colorectal cancer treatment: Conatumumab decorated, reactive oxygen species sensitive irinotecan prodrug and quercetin co-loaded nanostructured lipid carriers.

Authors:  Youqiang Liu; Hongxin Zhang; Haijing Cui; Futong Zhang; Liyan Zhao; Yibing Liu; Qingju Meng
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.419

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.